Propranolol treatment of paruresis (psychogenic urinary retention): a brief case report

Propranolol, a nonselective beta-blocker, was administered to a client with paruresis (psychogenic urinary retention) following a novel in vivo exposure treatment. The client did not report a significant increase in his ability to urinate in public facilities during subsequent exposures. Rationale for including propranolol as an adjunct to exposure therapy of paruresis is discussed.